Twitter | Search | |
Benjamin Besse
Medical Oncologist - Lung cancer & thymic tumors. Head of the Cancer Medicine Dpt - Chair of the Lung Cancer Group .
156
Tweets
83
Following
3,550
Followers
Tweets
Benjamin Besse Jun 1
Smart chemos (=ADCs): a new way to merge target & chemo. 2 main settings for future trials: - 1st line when very high ORR & highly selected pts (ex. HER2mut) - 2nd line post CT-IO (vs. docetaxel) for targets frequently expressed by IHC (ex. CAECAM5, TROP2...).
Reply Retweet Like
Benjamin Besse May 31
Adjuvant EGFR TKI — ADAURA — HR 0.17 for DFS will impact OS? Events delayed after 3yrs of osi? Remember OPTIMAL (erlo in advanced NSCLC): HR 0.16 for PFS & HR 1.19 for OS, with longer FU and 69% cross over to TKI. Adjuvant treatment must CURE, not only delay recurrence.
Reply Retweet Like
Benjamin Besse May 31
CT-IO in SCLC — KN604 — OS curves : ~copy/paste of other studies, these (now familiar) shapes suggest only 10% of pts really derive an IO benefit. How to select pt? Our REACTION ph2 randomized only chemosensitive pts after 2xEP. Enrollment completed!
Reply Retweet Like
Benjamin Besse retweeted
Jose Carlos Benitez May 30
✅TETs are rare but very interesting for studying 🧬autoimmune diseases and 📍immunotherapy. 🗑️RYTHMIC network has systematically discussed up to 3000 patients with TET in France since 2012📊📈
Reply Retweet Like
Benjamin Besse May 30
A lot of pts/centers can’t afford a molecular testing. Our AI powered tool helps you to order the molecular tests that have the higher chance to be positive! Just enter your pt’s characteristics. Academic initiative = free access!
Reply Retweet Like
Benjamin Besse May 30
OX40, IDO1, TIGIT... We all fear too promising data — CITYSCAPE — Atezo+anti-TIGIT in PD-L1+ NSCLC I have the CTLA4 story in mind and I’m puzzled by 1) absence of benefit in the PD-L1 1-49% strata & 2) little differences in the immune mediated AEs. ⬇️Remember ASCO2018⬇️
Reply Retweet Like
Benjamin Besse May 29
What about ipi-nivo in PD-L1+ NSCLC ? — 9LA vs CM227 — Hard to conclude because none of the control arms are SoC (CT-IO) although high OS in CM227 with 14.9mo due to 71% cross over to 2nd line IO! 2 cycles of chemo decrease the risk of early progression (HPD?) w ipi-Nivo.
Reply Retweet Like
Benjamin Besse May 29
So what is best for non-squamous NSCLC? — 9LA vs KN189 — Look at the aligned 1yr OS bellow: quite similar! Of note, median OS of the control arm in 9LA > KN189 although cross over to IO 34% vs 54% in KN189 ! More selected population in 9LA?
Reply Retweet Like
Benjamin Besse May 21
Revival of preop treatments: another magic touch of IO? Let’s see the data in Current panorama and challenges for neoadjuvant cancer immunotherapy
Reply Retweet Like
Benjamin Besse Apr 10
Pharma funded report in the NEJM. Data from an EAP. 61 pts with severe Covid-19. 11% (n=7) excluded («no post-D1 clinical data») although all were hospitalized. I strongly criticize drug buzz when I train my interns. We must never lower our standards.
Reply Retweet Like
Benjamin Besse Apr 9
After CT-IO in pts with non-Sq NSCLC, another alternative to docetaxel! In our phase III study, weekly pacli + bev. increases PFS (primary endpoint, HR 0.61) and induces 4X more objective responses. .
Reply Retweet Like
Benjamin Besse Mar 16
ELCC2020 Congress is cancelled. Wise decision from ESMO and IASLC. Our Lung Cancer Group spring meeting (planned in Geneva 1d before ELCC) is also cancelled. We need to dedicate our energy and determination into the Covid19 battle! May the Force be with you all!
Reply Retweet Like
Benjamin Besse Jan 29
ICI might need a chemo boost when they face large (and aggressive?) tumors. In such cases, CT+ICI might be better that ICI alone for patients with NSCLC and TPS PD-L1>50%.
Reply Retweet Like
Benjamin Besse Dec 14
Oncogene-addicted NSCLC 1. CtDNA positive in only 52% of pts w isolated CNS PD vs. 84-92% of pts w extra CNS PD, p<0.0001 2. Pts w isolated CNS PD & ctDNA+ more at risk of extra CNS PD (32 vs 7%, p=0.026)
Reply Retweet Like
Benjamin Besse Dec 10
One or Two Immune Checkpoint Inhibitors? Question is valid for both melanoma and NSCLC. Different perspectives (ipi dose, duration of treatment, biomarkers, relevance of the control arm...), no definitive answer.
Reply Retweet Like
Benjamin Besse Nov 25
Anti-drug Antibodies Against IO: good or bad news? We reviewed the latest FDA & EMA data. Although rates differ according to drugs (and their tests), results are conflicting and we have no definitive answer yet for pts with NSCLC.
Reply Retweet Like
Benjamin Besse Nov 25
Strong voice of in the Be Mut-ual Days, fantastic event organized by Silvia Novello . More than 80 patients with oncogene addicted NSCLC along with their physicians and relatives! These meetings are essential and much too rare.
Reply Retweet Like
Benjamin Besse Oct 12
The ‘official’ adverse events from trials do not reflect pts’ reality: - fatigue in >80% - cramps & muscle weakness in ~50% - 30-41% have thought about suicide. We must do better. Impressive study by and great discussion at
Reply Retweet Like
Benjamin Besse Sep 30
During my year in Barcelona (in Pr Rosell‘s lab), I grew up in many ways. Science, Medicine, and much, much more personally. This would have never happened without fellowship. I strongly recommand our young fellows to apply and live such lifetime experience.
Reply Retweet Like
Benjamin Besse Sep 29
Test the blood concentration of TKIs! New evidences that TKI dose matters. Might be even more important for brain progression. Very simple interventions (food effect, stop co-medicactions such as PPIs...) can help to increase the blood level of the TKI.
Reply Retweet Like